Search Results - "Ciferská, H."

C1q complement component and -antibodies reflect SLE activity and kidney involvement by Horák, P., Heřmanová, Z., Zadražil, J., Ciferská, H., Ordeltová, M., Kusá, L., Žurek, M., Tichý, T.

Get full text

High mobility group box-1 (HMGB-1) in osteoarthritic cartilage by HEINOLA, T, KOURI, V.-P, CLARIJS, P, CIFERSKA, H, SUKURA, A, SALO, J, KONTTINEN, Y. T

“…Nucleosomal high mobility group box-1 (HMGB-1) is translocated and released from necrotic and activated cells as an endogenous danger signal (alarmin) and…”
Get full text

Protocol Biopsy of a Transplanted Kidney as a Tool for Monitoring Adequacy of Immunosuppressive Therapy: 10 Years of Experience From a Single Transplant Center by Krejčí, K, Tichý, T, Al-Gabri, S, Horák, P, Ciferská, H, Hrubý, M, Horčička, V, S̆trebl, P, Z̆amboch, K, Bachleda, P, Zadraz̆il, J

“…Abstract Background The aims of this prospective study were to determine the prevalence of clinically silent rejection changes and of nephrotoxicity of…”
Get full text

C1q complement component and -antibodies reflect SLE activity and kidney involvement by Horák, P, Hermanová, Z, Zadrazil, J, Ciferská, H, Ordeltová, M, Kusá, L, Zurek, M, Tichý, T

“…The role of the complement system in the pathogenesis of systemic diseases is very ambivalent. In systemic lupus erythematosus (SLE), many abnormalities in the…”
Get full text

Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys – a preliminary pilot study by Ciferska, H, Horak, P, Konttinen, YT, Krejci, K, Tichy, T, Hermanova, Z, Zadrazil, J

“…We hypothesized that nucleic acids, free and/or complexed, filtered and/or locally released, might be entrapped in the kidneys because of the specific nucleic…”
Get full text

Merkel cell skin carcinoma by Krejcí, K, Zadrazil, J, Tichý, T, Horák, P, Ciferská, H, Hodulová, M, Zezulová, M, Zlevorová, M

“…Merkel cell carcinoma is a rare tumour of the skin. It affects predominantly elderly Caucasian males on sun-exposed areas of the skin. Distinctively more…”
Get more information

Résultats de phase 2 d’efficacité et de tolérance jusqu’à 52 semaines du ianalumab, anti-BAFF récepteur (BAFF-R), chez les patients atteints de lupus érythémateux systémique (LES) by Lazaro, E., Agmon-Levin, N., Ignatenko, S., Gordienko, A., Cortes-Hernandez, J., Narongroeknawin, P., Romanowska-Prochnicka, K., Shen, N., Ciferska, H., Kodera, M., Wei, C.C., Leszczynski, P., Lan, J.L., Mysler, E., Wojciechowski, R., Tarr, T., Vishneva, E., Chen, Y.H., Kaneko, Y., Finzel, S., Hoi, A., Okada, M., Koolvisoot, A., Lee, S.S., Dai, L., Kaneko, H., Rojkovich, B., Sun, L., Zotkin, E., Magallares, B.P., Sengupta, T., Sips, C., Oliver, S., Avrameas, A., Lau, C.

“…Ianalumab est un nouvel Ac monoclonal IgG1 humain défucosylé ciblant le BAFF-R, induisant à la fois une déplétion augmentée (afucosylée) des cellules B et un…”
Get full text

Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes by Horák, P, Hermanová, Z, Ordeltová, M, Faltýnek, L, Kusá, L, Budíková, M, Vavrdová, V, Opíchalová, D, Ciferská, H, Scudla, V

“…Goal of this study was to monitor levels of serum neopterin and soluble interleukin-2 receptor (sIL-2r) and to evaluate their importance in monitoring activity…”
Get more information